Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Drug Resistance in Targeted Cancer Therapy"
Deadline for manuscript submissions: closed (15 November 2019).
Interests: molecular mechanisms of drug activity; anticancer drugs; targeted agents; drug resistance; pharmacogenetics; pancreatic cancer; lung cancer
Fax: +39 09123860854
Interests: drug discovery; kinases; cancer; pharmacology; biological drugs; drug resistance
Special Issues and Collections in MDPI journals
During the last decade, new and rationally designed drugs have been developed to neutralize specific molecules or genes involved in the development of cancer, appropriately called “targeted agents”. Most of these novel agents interact with receptors or signalling molecules, that are pivotal in tumor growth and development, and they can inhibit cancer cell proliferation, or induce programmed cell death. However, these drugs have been approved only for a limited number of malignancies, and further studies to evaluate novel applications, as well as identify biomarkers to guide these treatments are warranted. Similarly, new appropriate drug combinations might represent a major strategy to overcome the reasons for their failures, such as inherent or acquired resistance, in different tumor types.
The present issue deals with the pharmacology of the most promising compounds targeting the key oncogenic pathways implicated in the development and progression of many tumor types through multiple effects on cell cycle progression, apoptosis, and invasion. Remarkably, they use a highly overlapping repertoire of signalling adaptors and downstream pathways, and are potential targets for different drugs.
Therefore, this Special Issue will provide readers working in the basic biomedical sciences as well as clinicians a comprehensive overview of novel effective anticancer compounds, with the aim of clarifying their development, pharmacology, resistance factors, and new strategies and applications, against major tumors.
Prof. Dr. Elisa Giovannetti
Prof. Dr. Patricia Diana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- anticancer drugs
- targeted agents
- drug resistance
- drug discovery